, vladimir makarov 3, 4 , vinod P. balachandran 5, 6, 7 , matthew D. Hellmann 7, 8, 9 , Alexander Solovyov 10, 11, 12, 13 , naiyer A. rizvi 14 , Taha merghoub 7, 15, 16 , Arnold J. Levine 1 , Timothy A. Chan 2, 3, 4, 7 , Jedd D. Wolchok 7, 8, 15, 16 & benjamin D. Greenbaum 10, 11, 12, 13 Checkpoint blockade immunotherapies enable the host immune system to recognize and destroy tumour cells 1 . Their clinical activity has been correlated with activated T-cell recognition of neoantigens, which are tumour-specific, mutated peptides presented on the surface of cancer cells 2,3 . Here we present a fitness model for tumours based on immune interactions of neoantigens that predicts response to immunotherapy. Two main factors determine neoantigen fitness: the likelihood of neoantigen presentation by the major histocompatibility complex (MHC) and subsequent recognition by T cells. We estimate these components using the relative MHC binding affinity of each neoantigen to its wild type and a nonlinear dependence on sequence similarity of neoantigens to known antigens. To describe the evolution of a heterogeneous tumour, we evaluate its fitness as a weighted effect of dominant neoantigens in the subclones of the tumour. Our model predicts survival in anti-CTLA-4-treated patients with melanoma 4,5 and anti-PD-1-treated patients with lung cancer 6 . Importantly, low-fitness neoantigens identified by our method may be leveraged for developing novel immunotherapies. By using an immune fitness model to study immunotherapy, we reveal broad similarities between the evolution of tumours and rapidly evolving pathogens [7] [8] [9] . Although T-cell receptors (TCRs) are capable of recognizing and eliminating tumours, cancers evolve resistance mechanisms by using checkpoint blockade molecules to disrupt the processes of immune recognition and attack. Clinical trials using immune checkpoint blocking antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed cell death protein-1 (anti-PD-1), have improved overall survival in many malignancies by inhibiting these checkpoints 1 . Although only a minority of patients achieve durable clinical benefit, multiple studies have presented genetic determinants of response. Non-synonymous de novo somatic mutations can create neoantigens-novel protein epitopes specific to tumours that may be presented by MHC molecules and recognized by T-cells as nonself 2, 3 . An increased number of mutations or putative neoantigens has been linked to improved response to checkpoint blockade therapy in multiple malignancies [4] [5] [6] 10 . Therefore, inferred neoantigen load is a coarse-grained proxy for whether a tumour is likely to respond. 18 , is therefore a highly sought-after goal.
. Although T-cell receptors (TCRs) are capable of recognizing and eliminating tumours, cancers evolve resistance mechanisms by using checkpoint blockade molecules to disrupt the processes of immune recognition and attack. Clinical trials using immune checkpoint blocking antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) or anti-programmed cell death protein-1 (anti-PD-1), have improved overall survival in many malignancies by inhibiting these checkpoints 1 . Although only a minority of patients achieve durable clinical benefit, multiple studies have presented genetic determinants of response. Non-synonymous de novo somatic mutations can create neoantigens-novel protein epitopes specific to tumours that may be presented by MHC molecules and recognized by T-cells as nonself 2, 3 . An increased number of mutations or putative neoantigens has been linked to improved response to checkpoint blockade therapy in multiple malignancies [4] [5] [6] 10 . Therefore, inferred neoantigen load is a coarse-grained proxy for whether a tumour is likely to respond. Other implicated biomarkers of response include TCR repertoire profiles 11 , assays of checkpoint status 12, 13 , immune microenvironment landscape 5, 14, 15 and tumour heterogeneity 16 . Despite high overall neoantigen load, a heterogeneous tumour may have immunogenic neoantigens that are present only in certain subclones. Therapies targeting a fraction of the tumour could disrupt clonal competitive balance and inadvertently stimulate the growth of untargeted clones 17 . Worldwide efforts are being undertaken to model neoantigens and quantify their features from genomic data. A predictive neoantigenbased model for immunotherapy response, complementing mass spectrometry-based neoantigen validation 18 , is therefore a highly sought-after goal.
We propose a fitness model of tumour-immune interactions as a general mathematical framework to describe the evolutionary dynamics of cancer cell populations under checkpoint blockade immunotherapy and provide a proof of concept for its utility (Fig. 1) . Analogous fitness models based on immune interactions have been successfully applied to human influenza 7 , HIV 8 and chronic viral infections 9 . Checkpoint blockade exposes cancer cells to strong immune pressure on their neoantigens, reducing their reproductive success. Our model predicts the evolutionary dynamics of a cancer cell population after a finite time under such pressure. We compute n(τ), the predicted future effective size of a cancer cell population in a tumour relative to its effective size at the start of therapy. The size is a weighted sum over all of the genetic clones of a tumour ( Fig. 1a and Methods),
where F α is the fitness, X α is the initial frequency of clone α and τ is a characteristic timescale over which predictions are evaluated. Because tumours may include other cell types, it is not to be interpreted as a direct measurement of physical tumour size. Patients with less immunologically fit tumours will have greater effective size reductions and, presumably, improved overall survival after therapy. The ancestral dependencies between clones determine the mutations and neoantigens inherited by clones from their ancestors. Our fitness model assigns to subclones the same or lower fitness than their ancestral clones, depending on whether they acquired new dominant neoantigens (Fig. 1a) . Our model quantifies essential factors for determining the immunogenicity of a neoantigen: the amplitude, A, determined by mutant and wild-type class I MHC presentation, and an intrinsic TCR-recognition probability, R (both are defined below). We call the product of these two factors, A × R, the recognition potential of a neoantigen. We quantify the total fitness of cancer cells in a clone by aggregating over the fitness effects that are due to immune recognition of its neoantigens letter reSeArCH 5 ( Fig. 1b and Methods). Here we model the fitness of a given clone α by the recognition potential of its dominant neoantigen,
i i i clone where the index i is iterated over all neoantigens in clone α (we discuss other choices for aggregating neoantigen fitness effects in the Methods).
We use neoantigens with a length of nine residues that are inferred by a consistent identification pipeline with affinities for both mutant and wild-type peptides in each patient 19 (Supplementary Information); we define the amplitude A using the relative MHC affinity of the wild-type and the mutant peptide (Methods). Despite having a difference of only a single mutation, inferred binding affinities for these peptides can be substantially different (Extended Data Fig. 1 ). Unlike parameters that consider only mutant or wild-type affinities, the amplitude provides a consistent predictive value within our model (Extended Data Table 1) . A simple interpretation is that the amplitude is related to the number of TCRs that are available to recognize the neoantigen. A neoantigen needs to have a low dissociation constant (that is, a strong binding affinity) to be presented and generate a TCR response. However, if the wild-type peptide also has a low dissociation constant, tolerance mechanisms could have removed TCRs that are specific to the wildtype peptide. Owing to cross-reactivity, the number of mutant-specific TCRs could be reduced (Methods).
We also estimate the intrinsic probability of a neoantigen being recognized by a TCR. Here we use the strength of alignment of each neoantigen to the positively recognized, class-I-restricted T-cell antigens from the Immune Epitope Database 20 (IEDB). This approach does not assume pre-existing host immunity due to the epitope set. Rather, we suggest that high-scoring neoantigens are more non-self. Because TCRs have intrinsic biases in their generation probability and can recognize large classes of peptides via cross-reactivity 21, 22 , we hypothesize that such neoantigens are more likely to be recognized. We use a consistent thermodynamic model to estimate this probability (Methods): for a neoantigen with peptide sequence s and IEDB epitope with sequence e, the alignment score between s and e estimates the binding free energy between s and a TCR that recognizes e. Notably, the probability that a neoantigen is bound by a TCR is given by a nonlinear logistic dependence on sequence alignment scores of the epitope set (Methods).
We apply our model to three datasets: two melanoma cohorts 4, 5 treated with anti-CTLA-4 and a non-small-cell lung cancer cohort 6 treated with anti-PD-1. Efficacy is assessed using overall survival of patients from the beginning of immunotherapy (Methods). Neoantigen anchor positions 2 and 9, for the majority of HLA types, are constrained by hydrophobic bias, as reflected by decreased amino acid diversity at these positions 23 (Extended Data Fig. 2 ). We found that computational predictions of MHC affinities for wild-type peptides with nonhydrophobic anchor residues led to non-informative amplitudes (Extended Data Tables 1, 2) . Therefore, neoantigens with mutations generated from non-hydrophobic, wild-type residues at positions 2 and 9 are excluded. The parameter τ in equation (1) sets the characteristic timescale for response to therapy. At time τ, clones with dominant neoantigens with amplitudes that are larger than 1/τ will have been suppressed. The model has two other free parameters, which define R; its midpoint and steepness (Methods). For each cohort, we infer parameters by maximizing the survival log-rank test score for independent training data.
We use the cohort of 64 patients with melanoma 4 to train parameters for 103 patients with metastases in the second melanoma cohort 5 and vice versa; we use the total score of both cohorts 4, 5 to train parameters for the smaller cohort 6 of 34 patients with lung cancer (Methods). For each cohort, we obtain significant stratification of patients: the logrank test P values are P = 0.0049 for the dataset from ref. 5 , P = 0.0026 for the dataset from ref. 4 and P = 0.0062 for the dataset from ref. 6 (Extended Data Table 1 ). The parameters that were obtained in this way are consistent between datasets and mutually included within the error bars of each of the other studies (Extended Data Table 1 and Methods) . We further performed a joint optimization of the cumulative log-rank test score of the three cohorts, obtaining a single set of parameters with predictions that are highly stable around these values (Extended Data Fig. 3 ). The alignment threshold parameter is consistently set to 26 (Extended Data Table 1 ), which in our datasets is obtained by alignments of a mean length of 6.8 amino acids, just above the average length of peptide motifs that would be expected to be discriminated by the TCR repertoire (Supplementary Information). The slope parameter is set to 4.87, defining dependence as a strongly nonlinear function of alignment score, with the recognition probability dropping below 0.01 for an alignment score of 25 and attaining a probability above 0.99 for an alignment score of 27 (Extended Data Fig. 4 ). The τ parameter is set to 0.09, which indicates that clones with amplitudes higher than 11.1 are, on average, suppressed at prediction time. With these consistent parameters, separation of patients does not change for the datasets from refs 5 and 6 (log-rank test score increases by less than 1 unit, P = 0.004 for the dataset from ref. 5 and P = 0.0062 for the dataset from ref. 6 ) and it improves to P = 0.00026 for the dataset from ref. 4 (Fig. 2) . Patient segregation by n(τ) evaluated at arbitrarily small τ (equivalent to the average tumour fitness over clones; Methods) is also significant (Extended Data Fig. 3 and Extended Data Table 1 ), suggesting that predictive power depends more on the model's ability to capture immune interactions than the duration of evolutionary projections. Finally, the predicted evolutionary dynamics of tumours separate therapy responders and non-responders, using patient classifications defined in the original studies [4] [5] [6] . In all datasets, responders are predicted to have significantly faster decreasing relative sizes n(τ) across a broad interval of τ values (Fig. 3) . The performance of the model deteriorates when we disrupt the biological relevance of input data. When using the IEDB epitopes not supported by positive T-cell assays, the model loses its predictive ability in both melanoma cohorts (Methods, Extended Data Table 1 and Extended Data Fig. 5) . Similarly, the model generally does not show significant patient separations when using neoantigens that were derived with randomized patient HLA types (Extended Data Fig. 6 and Supplementary Information).
The success of our model strongly depends on the joint contribution of A and R in equation (2) . We constructed partial models with only one component and repeated the same training and validation procedure as in the full model, with survival analysis separating patients into equalsized groups ( Fig. 2 and Extended Data Table 1 ). For all datasets, partial models had lower log-rank scores than the full model and neither the A-nor the R-only model resulted in significant segregation for any cohort. We compare our full model with a neoantigen load model, which assigns a uniform fitness cost to each neoantigen. This model does not significantly separate patients by median in either cohort ( Fig. 2 and Extended Data Table 1 ). We assess the importance of tumour clonal structure for our identification of dominant neoantigens. For all datasets, our full clonal model performed better than an alternative model that assumed homogenous tumour structure (Fig. 2 ). Clonality appears less important in partial models, which have either marginal or no statistical significance ( Fig. 2 and Extended Data Table 2 ). Moreover, our model is predictive independent of other clinical correlates (proportional hazard model; Extended Data Table 3 ).
Our framework enables straightforward incorporation of information about the microenvironment of the tumour. For the cohort from ref. 5 , gene expression data are available for 40 patients and local cytolytic activity is significantly associated with benefit (P = 0.04; Methods), which was also observed in the original study 5 . As a proof of principle, we incorporated cytolytic score 24 as an amplitude multiplying the T-cell recognition probability. Its inclusion improves predictions for these 40 patients, as assessed using survival analysis (P = 0.043 and P = 0.0025, respectively; Extended Data Fig. 7 ).
Immune interactions govern the evolutionary dynamics of cancers under checkpoint blockade immunotherapy and many rapidly evolving pathogens; fitness models can predict such dynamics over limited periods into the future, as has recently been shown for human seasonal influenza 7 . However, influenza evolution is determined by antigenic similarity with previous strains in the same lineage, whereas cancer cells acquire somatic mutations in a large set of proteins. Therefore, the cancer immune interactions are distributed in a larger and less homogenous antigenic space. The fitness effects of these interactions have a specific interpretation: they capture neoantigen non-selfness.
Our model formalizes what makes a tumour immunologically different from its host, analogous to models for innate recognition of non-self nucleic acids 25 . The approach can be extended to other fitness effects, such as positive selection owing to acquisition of driver mutations, the impact of additional components in the microenvironment or the hypothesized role of the microbiome 26, 27 . Further advances in predicting proteosomal processing 18 and stability 28 of neoantigen-MHC binding could improve predictions. Our framework should be useful for studies of acquired resistance to therapy and may be crucial for understanding when cross-reactivity with self-peptides may result in side effects 29, 30 . Because our fitness model is based on specific interactions underlying presentation and recognition of neoantigens, it may also inform the choice of therapeutic targets for tumour vaccine design.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. letter reSeArCH
MethOdS
Evolutionary dynamics of a cancer cell population in a tumour. The fitness of a cancer cell in a genetic clone α is its expected replication rate, that is,
where N α is the population size of clone α and F α is the fitness of that clone. Checkpoint blockade immunotherapy introduces a strong selection challenge, which we anticipate affects pre-therapy fitness effects in a productive response. For a given clone α , the dynamics of its absolute size are therefore given by N α (τ) = N α (0) exp(F α τ) and the total cancer cell population size is computed as a sum over its clones
The absolute size N(τ) is an effective population size, the number of cells estimated to have generated the observed clonal diversity. As our measure of survival, we use the evolved relative effective population size n(τ) = N(τ) / N(0), which compares the predicted future population size after a characteristic dimensionless timescale of evolution, τ, to the initial pre-treatment effective size N(0), with the assumption that successful responders to therapy will have their future effective cancer cell population size more strongly suppressed. We denote the initial frequency of clone α as X α = N α (0) / N(0); these frequencies are inferred from bulk exome reads from a tumour sample, as described in the Supplementary Information. Therefore, to compute n(τ), we only require estimates of the initial frequencies and fitness values for each clone, as shown in equation (1); the absolute population size estimates are not needed. We model the hypothesis that because of a T-cell-mediated immune response by checkpoint blockade immunotherapy, the deleterious effects caused by the recognition of neoantigens are a dominant fitness effect, and tumours with the greatest degree of selective immune challenge are better responders to therapy. Clonal structure of a tumour and clone frequencies. To reconstruct the clonal tree structure of a tumour from exome-sequencing data, we use a likelihood scheme based on the allele frequencies of its mutations 31 (Supplementary Information). The trees estimate the nested clonal structure of the tumour and the frequency of each clone, X α . The differences between the high scoring trees are marginal for our data, concerning only peripheral clones and small differences in frequency estimates. We computed the predicted relative size of a cancer population, n(τ), as an averaged prediction over the five trees with the highest likelihood score, weighting their contribution proportionally to their likelihood. Neoantigen recognition-based fitness cost for a tumour clone. Our model associates each neoantigen with a fitness cost, which we term the recognition potential of a neoantigen. The recognition potential of a neoantigen is the likelihood that it is effectively recognized by the TCR repertoire. It is defined by two components. The first is the amplitude, A, which is given by the relative probability that a neoantigen is presented on class I MHC and the relative probability that its wild-type counterpart is not presented. The second is the probability, R, that a presented neoantigen will then be recognized by the TCR repertoire. For a given neoantigen their product defines the recognition potential, A × R. Both components are described in detail below.
To assess the total fitness effect for a clone α with multiple neoantigens, we aggregate individual neoantigen fitness effects as = − ×
where i is an index iterating over all neoantigens in the clone. Therefore, the full form of the predicted relative cancer cell population size is given by
One could use a more general model for aggregating neoantigen fitness effects within a clone, . In addition to equation (5) , which corresponds to the limit β → ∞, we show the case where β = 0 (uniform summation across all neoantigens; Extended Data Table 1 ). Equation (6) therefore represents a general mathematical framework for weighing neoantigen contributions, with weights reflecting the probability of their productive recognition. The choice of β could be informed by additional data sources or defined in a clonespecific manner, and it would then become an additional model parameter (or parameters). Taking the highest score within a clone as in equation (5) is consistent with notions of immunodominance-that a relatively small set of antigens drive the immune response. MHC amplitude. The amplitude, A, is the ratio of the relative probability that a neoantigen is bound to a class I MHC times the relative probability that the wild-type counterpart of a neoantigen is not bound. The amplitude is defined as
MT , where P B MT is the binding probability of a neoantigen, P B WT is the binding probability of its wild-type counterpart, and
MT . As a result, the amplitude rewards cases where the discrimination energy between a mutant and wild-type peptide by the same class I MHC molecule (that is, the same HLA allele) is large 32 , while the mutant binding energy is kept low. The τ parameter effectively sets this energy scale for dominant neoantigens in a clone when R = 1. Assuming similar concentrations for mutant and wild-type peptides, the amplitude becomes the ratio of wild-type to mutant dissociation constants,
Negative thymic selection on TCRs is not absolute, but rather, it 'prunes' the repertoire recognizing the self proteome 33, 34 . We therefore use A as a proxy for the availability of TCRs in the repertoire to recognize a neoantigen. Neoantigens differ from their wild-type peptides by only a single mutation. Given the uniqueness of nonamer sequences in the self-proteome owing to a finite genome size (Supplementary Information), it is highly improbable that the mutant peptide would have another octamer match in the human proteome, so we only account for the comparison with the respective wild-type peptides. We verified that the above is the case for 92% of all neoantigens, with the remainder largely emanating from gene families with many paralogues (Supplementary Information). The amplitude can be interpreted as a multiplicity of receptors available to cross-reactively recognize a neoantigen.
MHC binding affinities are inferred as IC 50 values for each peptide sequence and patient HLA type 19 ; all mutant peptide sequences considered to be neoantigens meet a standard 500 nM cut-off (Supplementary Information). NetMHC 3.4 occasionally predicts very high values where training may be limited, and creates small denominators that can inflate the amplitude. In melanoma and lung cancer, a high mutational burden inflates the frequency of such events. As a remedy, a pseudocount, ε, is introduced so that, for both mutant and wild-type peptides,
. In this case, the new dissociation constant divided by peptide concentration becomes To fix these scales, we note that assays to determine dissociation constants for peptide-MHC binding are typically performed at 0.1-1 nM, under conditions where the ligand concentration is small compared to the dissociation constant 35 . For such conditions, when affinities can be interpreted as dissociation constants, 3,687 nM is an upper boundary 35 and ε/[L] is therefore chosen to be 0.0003 ≈ 1/3,687 across datasets.
As the affinity is always less than 500 nM for the mutant peptide, this correction is only relevant for the wild-type peptides. The corrected amplitude then becomes
The amplitude in this form, with inferred affinities standing in for dissociation constants, and combined with the TCR-recognition term discussed below, has a high predictive value for predictions of patient survival (Fig. 3) , consistently over the three patient cohorts and this is not the case for either the mutant or wild-type dissociation constants on their own (Extended Data Table 1 ). TCR recognition. We estimate R, the probability that a neoantigen will be recognized by the TCR repertoire, by alignment with a set of epitopes given by the Immune Epitope Database and Analysis Resource 20 (IEDB, described in the Supplementary Information). We restricted ourselves to linear epitopes from human infectious diseases that are positively recognized by T cells after class I MHC presentation. We assumed that a neoantigen predicted to cross-react with a TCR from this pool of immunogenic epitopes is a neoantigen that is more likely to be immunogenic itself, as members of the TCR repertoire both recognize a high number of presented antigens 36, 37 and have intrinsic biases in their generation probabilities 21 .
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We use a multistate thermodynamic model to define R. In the model, we treated sequence similarities as a proxy for binding energies. To assess sequence similarity between a neoantigen with peptide sequence s and an IEDB epitope e, we compute a gapless alignment between the two sequences with a BLOSUM62 amino acid similarity matrix 38 and denote their alignment scores as | | s e , , Given these sequence similarities, for a given neoantigen with peptide sequence s, we compute the probability that it is bound to a TCR specific to some epitope e from the IEDB pool as
where a represents the horizontal displacement of the binding curve, k sets the steepness of the curve at a, and
e IEDB is the partition function over the unbound state and all bound states. k functions as an inverse temperature and − s e a , functions as the binding energy. These parameters define the shape of the sigmoid function (Extended Data Fig. 4 ) and, along with the characteristic timescale, τ, are free parameters to be fit in our model.
The parameters that consistently give informative predictions across all three datasets are a = 26 and k = 4.87. The logistic function is therefore a strongly nonlinear function of the effective alignment score,
e IEDB . The average alignment length corresponding to a score of 26 is 6.8 for neoantigens in our datasets, but the effective alignment score is occasionally increased by multiple contributions of shorter alignments. For the interpretation where, for a sufficiently presented neoantigen, A represents the multiplicity of available TCRs and R represents an intrinsic probability of recognition, A × R represents the effective size of the overall TCR response. We present it as a core quantity that can be modulated by additional environmental factors such as T-cell infiltration (discussed below in paragraph "Inclusion of microenvironment and proteosomal processing in fitness model"). IEDB sequences. The predictive value of R depends on the input set of IEDB sequences. The set that we used in our analysis contained 2,552 unique epitopes (Supplementary Information). We tested how the predictions depend on the content and size of the dataset by performing iterative subsampling of IEDB sequences at frequencies varying from 10% to 90% of the total set size. We repeated the survival analysis and log-rank test score evaluation (Extended Data Fig. 5 ). For all three datasets removal of sequences had, on average, a negative impact on their predictive power, which monotonically decreases with the subsampling rate. In the cohort from ref. 5, median performance was already below significance at 70% subsampling and below, and for the cohorts from refs 4, 6 at 20% and below. To investigate the biological input associated with the set of curated IEDB sequences that we used, we also evaluated the R component using an alternative set of IEDB sequences, obtained from T-cell assays that did not have a positive validation. This is a larger set of 4,657 sequences. In the two melanoma datasets, the predictions became worse and did not give significant separation of patients in the survival analysis. This effect was not due to the different sequence set size-subsampling of sequences did not improve the outcome. Although for the dataset from ref. 6 , the predictions were still significant, this significance was not supported by consistency between all three datasets, as was observed with the IEDB sequence set with positive assays. Inclusion of microenvironment and proteosomal processing in fitness model. The role of the microenvironment in the likelihood of productive T-cell recognition of tumour neoantigens can be incorporated in a natural manner into our modelling framework. We used the cytolytic score (CYT), the geometric mean of the transcript per million kilobases of perforin and granzyme 24 . We did so for the 40 patients from the anti-CTLA4 melanoma dataset from ref. 5 , which have matched genome and transcriptome sequencing and where CYT had been shown to have predictive value. For this set we also derived the CD8 T-cell fraction using CIBERSORT 39 . The two values have a Pearson's correlation coefficient of 0.938. Given their encapsulation of similar information, we used CYT as it has previously been shown to give significant segregation of patient benefit 5 . The score provides an additional amplitude, A CYT , and the recognition potential becomes A CYT × A × R. Therefore, the cytolytic score amplifies the recognition potential by the degree of cytolytic activity (Extended Data Fig. 7) . We attempted to include proteosomal processing into our model as an additional criterion, as evaluated with NetCHOP 40 . We tested this procedure on the cohort from ref. 6 ; however, the imposed stronger filtering of neoantigens leads to the loss of predictive power for the model. Parameter training. To choose model parameters a and k in equation (10) and the characteristic time τ at which the prediction is evaluated (equation (5)), we selected the parameters that maximize the log-rank test scores of the survival analysis of the patient cohorts. The survival analysis is performed by splitting the patient cohort by the median value of n(τ) into high and low fitness groups. For each cohort, we performed parameter training on independent data: we used the melanoma cohorts to train parameters for each other by using the maximal score of one to define parameters for the other, and we used both melanoma cohorts and maximization of their total log-rank test score to train parameters for the lung cancer cohort. To infer consistent parameters between all datasets, we maximize the total log-rank test score across the three cohorts.
For a given training set, we computed the optimal parameters τ Θ = a k ( , , ) as an average Θ = Θ w over a distribution Θ w( ) defined by the log-rank test score landscape for the set
1 max where Z(λ) is the probability distribution normalization constant, Θ S( ) is the value of the log-rank test score with parameters Θ, and S max is the maximal score value obtained across all possible parameters. The weight parameter λ is chosen such that the total statistical weight of the suboptimal parameter region is less than 0.01, the suboptimal scores are those less than max(3.841, S max − 2) (where 3.841 is the score value corresponding to P = 0.05 of the log-rank test score). Using a smooth local neighbourhood of parameters around the optimal values prevents over-fitting on a potentially rugged score landscape. For each individual parameter, the error bars reported in Extended Data Tables 1 and 2 are computed as the standard deviation using the marginalized probability distribution Θ w( ) for this parameter. The survival score landscapes (Extended Data Fig. 3 ) are consistent between the datasets. The optimal value of parameter a, the midpoint of the logistic binding function, is around 26 and parameter k, the steepness of the logistic function, is on a trivial axis above a value of 4, suggesting that there is a strong nonlinear fitness dependence on the sequence alignment score. Model selection. Alternative fitness models. We compared our full model in equation (5) to alternative models. We performed simple model decompositions, where only one component was used
and tested various variants of the model, with and without the R component,
We investigated how informative the alignments contributing to the R i components are and we tested a model where alignments were restricted to the 6 residues in between anchor positions, for positions 3-8. We also demonstrate the loss of predictive power for a model that does not implement any filtering of neoantigens mutated on positions 2 and 9 (Extended Data Fig. 2) . We reduced the problem of choosing the neoantigen-aggregating function to that of model selection. We tested a model where fitness was defined by the total effect of all neoantigens in the clone (which is the limit in case of β = 0 in equation (6)),
Finally, we formulate a simple fitness model that associates a constant fitness cost with each neoantigen,
where L α is the number of neoantigens in clone α , referred to as the neoantigen load of clone α . Homogenous structure models. For each fitness model, we defined its homogenous structure equivalent, which assumed that a tumour is strictly clonal with all neoantigens in the same clone at a frequency 1. In a homogenous model, the population size is therefore modelled by a simple exponential,
where F is the fitness of the homogenous tumour. Because, in this model, tumours show a constant decay over time, ranking of n(τ) values for patients is defined only letter reSeArCH by fitness and does not depend on τ. Therefore, τ is not a free parameter in these models when optimizing log-rank test score in survival analysis.
Average fitness. We also investigated the average fitness of clones,
as a predictive marker for patients and an alternative to n(τ). The average fitness reflects the rate at which the tumour cell population is decreasing in size at the beginning of therapy. For the purpose of patient ranking, it is equivalent to n(τ) at infinitesimally small values of the time parameter τ. This is a lower complexity model, because τ is not a free parameter. However, this model is less robust to outliers-small clones with very low fitness can dominate the average fitness, whereas the evolutionary projection in n(τ) removes such effects. Predictive power. We assessed the predictive power of all models using survival analysis, separating patients into equally sized groups using the median value of n(τ) or the median value of the average fitness F within the cohort. We used a logrank test, the results of this comparison are reported in Extended Data Table 1 , and in Extended Data Table 2 for models that disregard tumour subclonal composition.
To assign error bars to fluctuations of the log-rank test score we performed a leaveone-out analysis. That is, we repeated the survival analysis for each dataset after leaving one sample in a cohort out and computed the standard deviation of the test statistic across all leave-one-out iterations. We claim that a fitness model is predictive if it gives patient segregation of highly significant scores in all datasets with the same consistent set of parameters. Only the full neoantigen fitness model meets these criteria. The results are highly significant when patient segregation is based on n(τ) values. The average fitness criterion from equation (20) marginally meets the above requirements for predictiveness, but with smaller significance (Extended Data Table 1 ).
Comparison with thresholded neoantigen load. In our survival analysis, we used a standard, non-optimized partitioning of patients into two equally sized groups by the median value of n(τ). This approach enabled unbiased comparison of models, and assigned a stringent predictive value. Our results do not contradict the earlier reported predictive quality of neoantigen load. Consistent with ref. 4 , we observed a significant split at a threshold value of 100 neoantigens or less. This threshold classifies more than 70% of the patients in a long-term surviving group; separation by total neoantigen load is not significant at lower fractional partitions, including the median. For ref. 5, the survival analysis was not originally presented and we did not see a significant separation of patients at any possible splitting by a neoantigen load threshold. Finally, the significant separation for the cohort from ref. 6 is observed for the 32-50% range of partitions, including by the median (Fig. 2 and Extended Data Table 1 ). It is worth noting that for this cohort, we used previously unpublished overall survival data, which differ from the progression-free survival data used by the original study 6 . For all cohorts, our neoantigen fitness model and partitioning based on the n(τ) parameter include significant separations at a larger range of partitions: 40-60% for the cohort from ref. 5 The violin plots represent the data density at a given value on the vertical axis. a, Neoantigens with mutations at position 2 or 9 tend to have wild-type peptides with larger predicted affinities. In particular, this is magnified if the corresponding wild-type residue is non-hydrophobic. b, Those biases are reflected by a wider distribution of amplitudes (Methods, equation (7)) for wild-type peptides with non-hydrophobic residues at positions 2 and 9. c, Shannon entropy of amino acid diversity by position in neoantigens, shown for all distinct HLA types and computed based on neoantigens across all datasets. Positions 2 and 9 have a lower entropy than other residues. Other sites have the same entropy as the overall proteome 23 and are therefore unconstrained. Five HLA profiles with non-canonical entropies are highlighted in the plot. These HLA types contributed only five informative neoantigens across all datasets and are therefore not treated differentially in our model. (1)). Error bars represent the standard error due to sample size. b, A model optimized for cytolytic score significantly separates patients (Methods). c, Inclusion of the cytolytic score in our model improves prediction for the subset of 40 patients. The P values from log-rank tests comparing the two Kaplan-Meier curves are shown above each plot. For a and c, we used consistent parameters trained on the three cohorts (Extended Data Fig. 2) ; for b, the parameter τ is optimized.
letter reSeArCH extended data table 2 | ranking of fitness models without accounting for the subclonal composition of tumours Fitness models from Extended Data Table 1 Table 1 , we report parameters used for predictions and error bars for these parameters (Methods). Parameter τ is not a free parameter when disregarding the subclonal composition of tumours (Methods) and is therefore not reported. We report the log-rank test scores for all models and the log-rank test P value for models with significant patient segregation (P < 0.05). The significant models are highlighted: yellow for models significant for a single cohort, orange for models significant across two cohorts, and red for models significant for all three cohorts. 
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Describe how samples/organisms/participants were allocated into experimental groups.
n/a
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
n/a
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
